Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2015 October;63(5) > Minerva Cardioangiologica 2015 October;63(5):411-26



Cite this article as


A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695




Minerva Cardioangiologica 2015 October;63(5):411-26


language: English

Cobalt chromium-based biodegradable polymer sirolimus-eluting stent: rationale, evidence and clinical experience

Pan D. R. 1, Zhu H. 1, Hu Z. Y. 1, Pang S. 2, Wu W. 1, Tian N. L. 1, Xu B. 3, Iqbal J. 4, Zhang Y. J. 1

1 Nanjing First Hospital, Nanjing, China; 2 Southeast University, Nanjing, China; 3 Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; 4 Sheffield Teaching Hospitals and the University of Sheffield, Sheffield, UK


Metallic drug-eluting stents (DES) are the first choice for percutaneous coronary interventional treatment of coronary artery disease at present. Although they have overcome some disadvantages and limitations of plain balloon angioplasty and bare-metal stents, chronic local inflammatory reactions related to permanent polymer existence and poor vascular healing after first generation DES implantation may translate into the increased risk of late and very late stent thrombosis. There have been technological developments in stent design, materials and coatings, including more conformable platform designs, biocompatible or biodegradable polymers and improved kinetics of drug release. The newer generation DES have proven superior to previous DES technology in terms of both safety and efficacy. Accumulating evidence has suggested that DES with cobalt chromium stent platform, modified biodegradable polymer coatings, and rapamycin derivative drugs are associated with improved clinical outcomes. Currently, several new cobalt chromium biodegradable polymer sirolimus-eluting stents have been introduced to clinical practice. This review will describe basic concept and rationale behind the newer cobalt chromium biodegradable polymer sirolimus-eluting stents, systematically present the new clinical experiences with several representative devices.

top of page

Publication History

Cite this article as

Pan DR, Zhu H, Hu ZY, Pang S, Wu W, Tian NL, et al. Cobalt chromium-based biodegradable polymer sirolimus-eluting stent: rationale, evidence and clinical experience. Minerva Cardioangiol 2015 October;63(5):411-26. 

Corresponding author e-mail